WO2008036718A3 - Mir-143 regulated genes and pathways as targets for therapeutic intervention - Google Patents

Mir-143 regulated genes and pathways as targets for therapeutic intervention Download PDF

Info

Publication number
WO2008036718A3
WO2008036718A3 PCT/US2007/078859 US2007078859W WO2008036718A3 WO 2008036718 A3 WO2008036718 A3 WO 2008036718A3 US 2007078859 W US2007078859 W US 2007078859W WO 2008036718 A3 WO2008036718 A3 WO 2008036718A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
pathways
targets
therapeutic intervention
regulated genes
Prior art date
Application number
PCT/US2007/078859
Other languages
French (fr)
Other versions
WO2008036718A2 (en
Inventor
Andreas G Bader
Mike Byrom
Charles D Johnson
David Brown
Original Assignee
Asuragen Inc
Andreas G Bader
Mike Byrom
Charles D Johnson
David Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asuragen Inc, Andreas G Bader, Mike Byrom, Charles D Johnson, David Brown filed Critical Asuragen Inc
Priority to EP07842750A priority Critical patent/EP2094848A2/en
Priority to CA002663812A priority patent/CA2663812A1/en
Priority to JP2009529357A priority patent/JP2010504349A/en
Priority to AU2007299873A priority patent/AU2007299873A1/en
Publication of WO2008036718A2 publication Critical patent/WO2008036718A2/en
Publication of WO2008036718A3 publication Critical patent/WO2008036718A3/en
Priority to IL197691A priority patent/IL197691A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)

Abstract

The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-143, using miR-143 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
PCT/US2007/078859 2006-09-19 2007-09-19 Mir-143 regulated genes and pathways as targets for therapeutic intervention WO2008036718A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07842750A EP2094848A2 (en) 2006-09-19 2007-09-19 Mir-143 regulated genes and pathways as targets for therapeutic intervention
CA002663812A CA2663812A1 (en) 2006-09-19 2007-09-19 Mir-143 regulated genes and pathways as targets for therapeutic intervention
JP2009529357A JP2010504349A (en) 2006-09-19 2007-09-19 Genes and pathways regulated by miR-143 as targets for therapeutic intervention
AU2007299873A AU2007299873A1 (en) 2006-09-19 2007-09-19 miR-143 regulated genes and pathways as targets for therapeutic intervention
IL197691A IL197691A0 (en) 2006-09-19 2009-03-19 Mir-143 regulated genes and pathways as targets for therapeutic intervention

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82617306P 2006-09-19 2006-09-19
US60/826,173 2006-09-19
US93957307P 2007-05-22 2007-05-22
US60/939,573 2007-05-22

Publications (2)

Publication Number Publication Date
WO2008036718A2 WO2008036718A2 (en) 2008-03-27
WO2008036718A3 true WO2008036718A3 (en) 2008-05-22

Family

ID=38866587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078859 WO2008036718A2 (en) 2006-09-19 2007-09-19 Mir-143 regulated genes and pathways as targets for therapeutic intervention

Country Status (6)

Country Link
EP (1) EP2094848A2 (en)
JP (1) JP2010504349A (en)
AU (1) AU2007299873A1 (en)
CA (1) CA2663812A1 (en)
IL (1) IL197691A0 (en)
WO (1) WO2008036718A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
CA3042401A1 (en) 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN110638828B (en) * 2019-10-16 2023-05-05 中国人民解放军军事科学院军事医学研究院 Use of substances inhibiting CWF19L1 protein activity and/or expression level in inhibiting RSV replication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2006128245A1 (en) * 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Targeting cells with altered microrna expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2006128245A1 (en) * 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Targeting cells with altered microrna expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKAO YUKIHIRO ET AL: "MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers", ONCOLOGY REPORTS, vol. 16, no. 4, October 2006 (2006-10-01), pages 845 - 850, XP002463963, ISSN: 1021-335X *
ESAU CHRISTINE ET AL: "MicroRNA-143 regulates adipocyte differentiation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 50, 25 October 2004 (2004-10-25), pages 52361 - 52365, XP002376644, ISSN: 0021-9258 *
MICHAEL M Z ET AL: "REDUCED ACCUMULATION OF SPECIFIC MICRORNAS IN COLORECTAL NEOPLASIA", MOLECULAR CANCER RESEARCH, XX, XX, vol. 1, no. 12, October 2003 (2003-10-01), pages 882 - 891, XP009051992, ISSN: 1541-7786 *

Also Published As

Publication number Publication date
CA2663812A1 (en) 2008-03-27
JP2010504349A (en) 2010-02-12
WO2008036718A2 (en) 2008-03-27
AU2007299873A1 (en) 2008-03-27
IL197691A0 (en) 2011-08-01
EP2094848A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008154333A3 (en) Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2009070805A3 (en) Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2008085797A8 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2008073921A3 (en) Mir-126 regulated genes and pathways as targets for therapeutic intervention
WO2008073922A3 (en) Functions and targets of let-7 micro rnas
WO2008036776A3 (en) Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2009044899A1 (en) Nucleic acid capable of regulating the proliferation of cell
WO2009121152A3 (en) Gene signatures
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2012058693A3 (en) Compositions and methods for inhibition of pcsk9 genes
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2010065787A3 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2011005566A3 (en) Aptamer-targeted sirna to inhibit nonsense mediated decay
WO2009090639A3 (en) Sirna compounds and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842750

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2663812

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009529357

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007299873

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007842750

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007299873

Country of ref document: AU

Date of ref document: 20070919

Kind code of ref document: A